Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this fall ● Multiple Synchrony digi

Event · Earnings
Original reporting
Published Aug 11, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$STXS
Bullish
medium confidence
Mentioned
$STXS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STXSBullishMed
01

Why it matters

Traders can update models using the reported Q2 revenue composition, margin profile, cash burn, and management’s explicit Q3 and Q4 recurring and system revenue expectations, plus a cash-flow profitability target in 1H 2027.

02

Market read

The filing is a decision update for STXS focused on accelerating recurring catheter revenue, initial system sales traction, and a quantified path to cash-flow profitability.

03

What to watch

Operating loss and adjusted losses remain sizable, free cash flow is negative ($3.7M), and gross margin split shows system margin at 29%, so execution on mix and manufacturing efficiency is critical.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 11, 2026, with same-day conference call

Background

This SEC 8-K (Item 2.02) reports Stereotaxis Q2 2026 results and business updates, including progress integrating the previously announced Robocath acquisition.

Company-level read

Ticker impact

$STXSBullishMedium confidence
Context

Stereotaxis reported Q2 revenue of $7.7M, recurring revenue growth, and guided recurring revenue to about $7M in Q3 and $8M in Q4.

Expected impact

Likely positive near-term bias if investors view the guidance and catheter adoption as de-risking the path to profitability, though dilution concerns may cap upside.

Evidence & confidence

The article provides multiple decision-grade datapoints: quarterly revenue mix, gross margin, free cash flow, liquidity (cash $10.5M, no debt), and forward guidance with a stated cash-flow profitability target in 1H 2027. However, it does not provide consensus comparisons or new regulatory/contract milestones beyond the described sales and acquisition integration.

Market effects

Supports the narrative of commercialization traction in surgical robotics and endovascular catheter platforms, potentially improving sentiment toward adjacent medtech robotics names.

Limited; primarily company-specific US medtech execution and hospital adoption signals.

Moderate; endovascular procedure technology adoption and FDA clearance references can influence broader medtech investor sentiment, but the disclosure is US-focused.

Counterpoint

Guidance may still be fragile because system revenue is expected to be flat at about $3M each quarter, while profitability depends on manufacturing ramp and recurring catheter supply stability.

Key entities

  • Stereotaxis, Inc.

    NYSE-listed surgical robotics and endovascular intervention company reporting Q2 results and providing Q3-Q4 revenue guidance.

  • Robocath

    Previously announced acquisition completed, described as strengthening robotic technology leadership and integration efforts.

  • GenesisX

    Robotic system referenced as having the first US hospital purchase to be installed this fall.

  • Synchrony

    Digital operating room systems referenced as sold and installed following FDA clearance in April.

Related articles

$STXSHigh

Why is Stereotaxis stock sliding today?

Stereotaxis (STXS) fell 14.6% after Q3 2026 results missed estimates, with a $0.07 adjusted loss per share and $8.9M revenue. Supply shortages of MAGiC catheters and a $24M convertible note financing at $1.21/share raised concerns. TD Cowen cut its price target to $2.00. The stock hit a 52-week low of $0.80.

$STXSMedAI 8/10

20 robotic heart procedures had no device-related adverse events.

Stereotaxis (NYSE: STXS) announced 100% clinical success and no device-related adverse events in 20 first-in-human robotic heart procedures using Robocath's next-generation system. The study, presented at TCT 2026, showed 95% technical success and no physician radiation exposure. Robocath is a subsidiary of Stereotaxis, focusing on advanced robotic innovations for interventional cardiology.

$STXSMedAI 8/10

Stereotaxis (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.